Skip to main content
Erschienen in: Medical Oncology 4/2007

01.12.2007 | CASE

Systemic lupus Erythematosus and IgA multiple myeloma: a rare association?

verfasst von: J. Bila, N. Suvajdzic, I. Elezovic, M. Colovic, D. Boskovic

Erschienen in: Medical Oncology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

The coexistence of systemic lupus Erythematosus (SLE) and multiple myeloma (MM) is uncommon and the pathogenetic mechanisms underlying this association remain unclear. We report the case of a woman who was diagnosed with SLE in 1993 aged 57, then developing IgA lambda type MM in the IIB clinical stage 7 years later. The SLE was treated successfully with methylprednisolone and chloroquine, and low dose maintenance steroid was continued with bisphosphonate protection until December 1994 when she suffered multiple vertebral fractures. She continued to receive 4 mg alternate day methylprednisolone and calcitonin until she decided to discontinue her own treatment 2 years later. In 2000, while still in stable SLE remission, she was diagnosed with MM. Protein electrophoresis revealed the IgA lambda paraprotein (40.5 g/l) and she had a Bence Jones (BJ) proteinuria of the lambda light chain type. Bone marrow trephine biopsy revealed a massive patchy infiltrate of abnormal plasmocytes (70%), while an extensive x-ray skeletal survey did not show any new fractures or osteolysis. The patient was treated according to the VMCP protocol without attaining a plateau phase. There was a similar poor clinical response to second and third line treatments (VAD, Thalidomide, Melphalan, and high dose dexamethasome). After 4 years of refractory disease the patient died from severe bilateral pneumonia. This case is discussed with reference to the literature.
Literatur
1.
Zurück zum Zitat Pettersson T, Pukkala E, Teppo L, Friman C. Increase risk of cancer in patients with systemic lupus Erythematosus. Ann Rheum Dis 1992;51(4):437–9.PubMed Pettersson T, Pukkala E, Teppo L, Friman C. Increase risk of cancer in patients with systemic lupus Erythematosus. Ann Rheum Dis 1992;51(4):437–9.PubMed
2.
Zurück zum Zitat Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus Erythematosus. Arthritis Rheum 1996;39(6):1050–4.PubMedCrossRef Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus Erythematosus. Arthritis Rheum 1996;39(6):1050–4.PubMedCrossRef
3.
Zurück zum Zitat Mellemkjaer L, et al. Non-Hodgkin′s lymphomas and other cancers among a cohort of patients with systemic lupus Erythematosus. Arthritis Rheum 1997;40(4):761–8. PubMedCrossRef Mellemkjaer L, et al. Non-Hodgkin′s lymphomas and other cancers among a cohort of patients with systemic lupus Erythematosus. Arthritis Rheum 1997;40(4):761–8. PubMedCrossRef
4.
Zurück zum Zitat Vineis P, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000;54(6):431–6.PubMedCrossRef Vineis P, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000;54(6):431–6.PubMedCrossRef
5.
Zurück zum Zitat Cibere J, Sibley J, Haga M. Systemic lupus Erythematosus and the risk of malignancy. Lupus 2001;10(6):394–400.PubMedCrossRef Cibere J, Sibley J, Haga M. Systemic lupus Erythematosus and the risk of malignancy. Lupus 2001;10(6):394–400.PubMedCrossRef
6.
Zurück zum Zitat Xu Y, Wiernik PH. Systemic lupus Erythematosus and B-cell hematologic neoplasm. Lupus 2001;10(12):841–50.PubMedCrossRef Xu Y, Wiernik PH. Systemic lupus Erythematosus and B-cell hematologic neoplasm. Lupus 2001;10(12):841–50.PubMedCrossRef
7.
Zurück zum Zitat Afeltra A, et al. Systemic lupus Erythematosus and multiple myeloma: a rare association. Semin Arthritis Rheum 1997;26(6):845–9.PubMedCrossRef Afeltra A, et al. Systemic lupus Erythematosus and multiple myeloma: a rare association. Semin Arthritis Rheum 1997;26(6):845–9.PubMedCrossRef
8.
Zurück zum Zitat Jordan E, Burnstein SL, Calabro JJ, Henderson ES. Multiple myeloma complicating the course of seronegative systemic lupus Erythematosus. Arthritis Rheum 1978;21(2):260–5.PubMedCrossRef Jordan E, Burnstein SL, Calabro JJ, Henderson ES. Multiple myeloma complicating the course of seronegative systemic lupus Erythematosus. Arthritis Rheum 1978;21(2):260–5.PubMedCrossRef
9.
Zurück zum Zitat Pehamberger M, Diem E, Konrad K. Systemic lupus Erythematosus with multiple myeloma. Acta Derm Venereol 1978;58(6):527–30.PubMed Pehamberger M, Diem E, Konrad K. Systemic lupus Erythematosus with multiple myeloma. Acta Derm Venereol 1978;58(6):527–30.PubMed
10.
Zurück zum Zitat Solary E, et al. Systemic lupus Erythematosus occurring in a patient with multiple myeloma. Arthrtis Rheum 1986;29(7):933–4.CrossRef Solary E, et al. Systemic lupus Erythematosus occurring in a patient with multiple myeloma. Arthrtis Rheum 1986;29(7):933–4.CrossRef
11.
Zurück zum Zitat Isobe T, Osserman EF. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci 1971;190:507–18.PubMedCrossRef Isobe T, Osserman EF. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci 1971;190:507–18.PubMedCrossRef
12.
Zurück zum Zitat Butler RC, Thomas SM, Thomson JM, Keat ACS. Anaplastic myeloma in systemic lupus Erythematosus. Ann Rheum Dis 1984;43:653–5.PubMed Butler RC, Thomas SM, Thomson JM, Keat ACS. Anaplastic myeloma in systemic lupus Erythematosus. Ann Rheum Dis 1984;43:653–5.PubMed
13.
Zurück zum Zitat Sendagorta E, Matarredona J, Brieva JA, Rodriguez ML, Ledo A. Systemic lupus Erythematosus in association with smoldering multiple myeloma. J Am Acad Dermatol 1987;16(1 pt 1):135–6.PubMed Sendagorta E, Matarredona J, Brieva JA, Rodriguez ML, Ledo A. Systemic lupus Erythematosus in association with smoldering multiple myeloma. J Am Acad Dermatol 1987;16(1 pt 1):135–6.PubMed
14.
Zurück zum Zitat Vaiopoulos G, Konstatopoulos K, Mantzourani M, Kaklamanis P. Multiple myeloma associated with systemic lupus Erythematosus. Leuk Lymphoma 2003;44(5):893–4.PubMedCrossRef Vaiopoulos G, Konstatopoulos K, Mantzourani M, Kaklamanis P. Multiple myeloma associated with systemic lupus Erythematosus. Leuk Lymphoma 2003;44(5):893–4.PubMedCrossRef
15.
Zurück zum Zitat Urbanska-Rys H, et al. Multiple myeloma in a patient with systemic lupus Erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma. Leuk Lymphoma 2004;45(9):1913–8.PubMedCrossRef Urbanska-Rys H, et al. Multiple myeloma in a patient with systemic lupus Erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma. Leuk Lymphoma 2004;45(9):1913–8.PubMedCrossRef
16.
Zurück zum Zitat Menon S, Snaith J, Isenberg DA. The association of malignancy with SLE.: an analysis of 150 patients under long term review. Lupus 1993;2(3):177–81.PubMed Menon S, Snaith J, Isenberg DA. The association of malignancy with SLE.: an analysis of 150 patients under long term review. Lupus 1993;2(3):177–81.PubMed
17.
Zurück zum Zitat Munzert G, Frickhofen N, Bauditz J, Schreiber S, Herrmann F. Concomitant manifestations of systemic lupus Erythematosus and low-grade non-Hodgkin’s lymphoma. Leukemia 1997;11(8):1324–8.PubMedCrossRef Munzert G, Frickhofen N, Bauditz J, Schreiber S, Herrmann F. Concomitant manifestations of systemic lupus Erythematosus and low-grade non-Hodgkin’s lymphoma. Leukemia 1997;11(8):1324–8.PubMedCrossRef
18.
Zurück zum Zitat Ramsey-Goldman R, Clarke A. Double trouble: are lupus and malignancy associated? Lupus 2001;10(6):388–91.PubMedCrossRef Ramsey-Goldman R, Clarke A. Double trouble: are lupus and malignancy associated? Lupus 2001;10(6):388–91.PubMedCrossRef
19.
Zurück zum Zitat Valeriano J. Malignancy and rheumatic disease. Cancer Control 1997;4(3):236–44.PubMed Valeriano J. Malignancy and rheumatic disease. Cancer Control 1997;4(3):236–44.PubMed
20.
Zurück zum Zitat Agudelo CA, Schumacher HR, Glick JH, Molina J. Non-Hodgkin’s lymphoma in systemic lupus Erythematosus: report of 4 cases with ultrastructural studies in 2. J Rheumatol 1981;8(1):69–78.PubMed Agudelo CA, Schumacher HR, Glick JH, Molina J. Non-Hodgkin’s lymphoma in systemic lupus Erythematosus: report of 4 cases with ultrastructural studies in 2. J Rheumatol 1981;8(1):69–78.PubMed
21.
Zurück zum Zitat Green JA, Dawson AA, Walker W. Systemic lupus Erythematosus and lymphoma. Lancet 1978;2(8093):753–6.PubMedCrossRef Green JA, Dawson AA, Walker W. Systemic lupus Erythematosus and lymphoma. Lancet 1978;2(8093):753–6.PubMedCrossRef
22.
Zurück zum Zitat Yoinou P, Le Corre R, Dueymes M. Autoimmune diseases and monoclonal gammopathies. Clin Exp Rheumatol 1996;14 Suppl 14:55–8. Yoinou P, Le Corre R, Dueymes M. Autoimmune diseases and monoclonal gammopathies. Clin Exp Rheumatol 1996;14 Suppl 14:55–8.
23.
Zurück zum Zitat Rubin L, Urowitz MB, Pruzanski W. Systemic lupus Erythematosus with paraproteinemia. Arthritis Rheum 1984;27(6):638–44.PubMedCrossRef Rubin L, Urowitz MB, Pruzanski W. Systemic lupus Erythematosus with paraproteinemia. Arthritis Rheum 1984;27(6):638–44.PubMedCrossRef
24.
Zurück zum Zitat Kelly C, Baird G, Foster H, Hosker H, Griffiths I. Prognostic significance of paraproteinemia in rheumatoid arthritis. Ann Rheum Dis 1991;50(5):290–4.PubMedCrossRef Kelly C, Baird G, Foster H, Hosker H, Griffiths I. Prognostic significance of paraproteinemia in rheumatoid arthritis. Ann Rheum Dis 1991;50(5):290–4.PubMedCrossRef
25.
Zurück zum Zitat Schafer AI, Miller JB. Association of IgA multiple myeloma with pre-existing disease. Br J Haematol 1979;41(1):19–24.PubMed Schafer AI, Miller JB. Association of IgA multiple myeloma with pre-existing disease. Br J Haematol 1979;41(1):19–24.PubMed
26.
Zurück zum Zitat Facon T, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97(6):1566–71.PubMedCrossRef Facon T, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97(6):1566–71.PubMedCrossRef
27.
Zurück zum Zitat Fonseca R, Oken MM, Greipp RP. Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001;98(4):1271–2.PubMedCrossRef Fonseca R, Oken MM, Greipp RP. Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001;98(4):1271–2.PubMedCrossRef
28.
Zurück zum Zitat Avet-Loiseau H, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58(24):5640–5.PubMed Avet-Loiseau H, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58(24):5640–5.PubMed
29.
Zurück zum Zitat Chang H, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125(1):64–8.PubMedCrossRef Chang H, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125(1):64–8.PubMedCrossRef
30.
Zurück zum Zitat Jaksic W, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J C Oncol 2005;23(28):7069–73.CrossRef Jaksic W, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J C Oncol 2005;23(28):7069–73.CrossRef
31.
Zurück zum Zitat Chesi M, et al. Frequent translocation t(4;14)(p16.3;q.32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genetics 1997;16(3):260–4.CrossRef Chesi M, et al. Frequent translocation t(4;14)(p16.3;q.32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genetics 1997;16(3):260–4.CrossRef
32.
Zurück zum Zitat Richelda R, et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves fibroblast growth receptor 3 gene. Blood 1997;90(10):4062–70.PubMed Richelda R, et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves fibroblast growth receptor 3 gene. Blood 1997;90(10):4062–70.PubMed
33.
Zurück zum Zitat Chesi M, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729–36.PubMedCrossRef Chesi M, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729–36.PubMedCrossRef
34.
Zurück zum Zitat Remmers EF, Sano H, Wider RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991;21(3):191–9.PubMedCrossRef Remmers EF, Sano H, Wider RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991;21(3):191–9.PubMedCrossRef
35.
Zurück zum Zitat Boumpas DT, Eleftheriades EG, Barez S, Tsokos GC. Oncogene expression and regulation in normal lymphocytes from patients with autoimmune disorders. Anticancer Res 1988;8(5A):977–84.PubMed Boumpas DT, Eleftheriades EG, Barez S, Tsokos GC. Oncogene expression and regulation in normal lymphocytes from patients with autoimmune disorders. Anticancer Res 1988;8(5A):977–84.PubMed
36.
Zurück zum Zitat Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 2002;100(10):3819–21.PubMedCrossRef Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 2002;100(10):3819–21.PubMedCrossRef
37.
Zurück zum Zitat Brown RD, Pope B, Luo XF, Gibson J, Joshua D. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymphoma 1994;16(1–2):147–56.PubMedCrossRef Brown RD, Pope B, Luo XF, Gibson J, Joshua D. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymphoma 1994;16(1–2):147–56.PubMedCrossRef
38.
Zurück zum Zitat Standal T, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100(8):3002–7.PubMedCrossRef Standal T, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100(8):3002–7.PubMedCrossRef
Metadaten
Titel
Systemic lupus Erythematosus and IgA multiple myeloma: a rare association?
verfasst von
J. Bila
N. Suvajdzic
I. Elezovic
M. Colovic
D. Boskovic
Publikationsdatum
01.12.2007
Verlag
Humana Press Inc
Erschienen in
Medical Oncology / Ausgabe 4/2007
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-0047-3

Weitere Artikel der Ausgabe 4/2007

Medical Oncology 4/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.